Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS.
Tokunaga, Keli, Sung, Alexander P, Tang, Jennifer J-J et al. · Work (Reading, Mass.) · 2020 · DOI
Quick Summary
Researchers studied immune cells called monocytes in ME/CFS patients and compared them to both healthy unrelated people and to family members without ME/CFS. They found that monocytes were slightly elevated in ME/CFS patients compared to unrelated healthy people, but when they compared patients to their own family members without the illness, the difference disappeared. This suggests that including unaffected family members as comparison groups helps researchers avoid mistakenly identifying false biomarkers.
Why It Matters
This research addresses a critical challenge in ME/CFS research: distinguishing true disease biomarkers from false positives caused by genetic or environmental factors shared within families. By proposing the inclusion of unaffected family members as controls, the authors provide a practical strategy for the field to accelerate biomarker discovery and avoid wasting resources pursuing non-specific findings.
Observed Findings
Non-classical monocytes were significantly elevated in ME/CFS patients compared to unrelated healthy donors.
Differences in non-classical monocyte levels between ME/CFS patients and their unaffected family members were not statistically significant.
Total monocyte counts showed similar patterns to CD16A-positive non-classical monocytes.
Family members without ME/CFS from multiply-affected families provided distinct comparison data from unrelated healthy controls.
The familial control approach efficiently ruled out monocyte populations as disease-specific biomarkers.
Inferred Conclusions
Family members without ME/CFS can serve as valuable second control groups to distinguish genetic/familial factors from disease-specific findings.
Non-classical monocyte elevation in ME/CFS may reflect familial or genetic factors rather than ME/CFS-specific pathology.
Including family members as controls can reduce wasted research effort on false biomarkers and optimize study design efficiency.
Occupational therapists and clinicians should encourage unaffected family participation in research studies to accelerate biomarker validation.
Remaining Questions
What is the shared genetic or environmental factor in affected families that influences monocyte levels in both patients and unaffected family members?
What This Study Does Not Prove
This study does not prove that non-classical monocytes are unrelated to ME/CFS pathophysiology—only that they cannot serve as a specific biomarker for diagnosis. The findings are preliminary pilot data and do not establish causation or the underlying mechanism of immune dysfunction in ME/CFS. The small sample size and focus on one immune cell type limit generalizability.